JP2025503480A5 - - Google Patents
Info
- Publication number
- JP2025503480A5 JP2025503480A5 JP2024537849A JP2024537849A JP2025503480A5 JP 2025503480 A5 JP2025503480 A5 JP 2025503480A5 JP 2024537849 A JP2024537849 A JP 2024537849A JP 2024537849 A JP2024537849 A JP 2024537849A JP 2025503480 A5 JP2025503480 A5 JP 2025503480A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- antigen
- heavy chain
- immunoglobulin heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292382P | 2021-12-21 | 2021-12-21 | |
| US63/292,382 | 2021-12-21 | ||
| PCT/US2022/082131 WO2023122659A2 (en) | 2021-12-21 | 2022-12-21 | Conditionally activated antigen binding polypeptide complexes and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503480A JP2025503480A (ja) | 2025-02-04 |
| JP2025503480A5 true JP2025503480A5 (cg-RX-API-DMAC7.html) | 2026-01-05 |
Family
ID=86903785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537849A Pending JP2025503480A (ja) | 2021-12-21 | 2022-12-21 | 条件付きで活性化される抗原結合ポリペプチド複合体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240059798A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452317A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503480A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240134257A (cg-RX-API-DMAC7.html) |
| CN (4) | CN118317979A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128060A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022420594A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240079A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001850A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313770A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007393A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334204A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023122659A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| WO2025249301A1 (ja) * | 2024-05-27 | 2025-12-04 | 国立大学法人東京農工大学 | 多重特異性抗体、がん増殖抑制剤、ポリヌクレオチド及び発現ベクター |
| CN121248779A (zh) * | 2024-06-25 | 2026-01-02 | 冕屹立生物技术(上海)有限公司 | 靶向人cd3分子的抗体及其应用 |
| WO2026092759A1 (en) * | 2024-11-04 | 2026-05-07 | Modex Therapeutics, Inc. | Multispecific antibodies and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9458244B2 (en) * | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
| ES2894304T3 (es) * | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| EA202091976A1 (ru) * | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| KR20210044218A (ko) * | 2018-07-11 | 2021-04-22 | 모멘타 파머슈티컬스 인코포레이티드 | CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| US12365722B2 (en) * | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| EP4578507A3 (en) * | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| US11613576B2 (en) * | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
| US20230001008A1 (en) * | 2019-08-20 | 2023-01-05 | Kumquat Biosciences Inc. | Compositions and methods for targeting cellular molecules |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN118613504A (zh) * | 2021-12-17 | 2024-09-06 | 摩德斯医疗股份有限公司 | 含有tnfsf配体的细胞外结构域的抗原结合多肽复合物 |
-
2022
- 2022-09-28 CN CN202280078695.8A patent/CN118317979A/zh active Pending
- 2022-09-28 CN CN202280078666.1A patent/CN118591388A/zh active Pending
- 2022-09-28 CN CN202280072889.7A patent/CN118251411A/zh active Pending
- 2022-12-21 MX MX2024007393A patent/MX2024007393A/es unknown
- 2022-12-21 TW TW111149263A patent/TW202334204A/zh unknown
- 2022-12-21 CN CN202280089147.5A patent/CN118715247A/zh active Pending
- 2022-12-21 AR ARP220103542A patent/AR128060A1/es unknown
- 2022-12-21 JP JP2024537849A patent/JP2025503480A/ja active Pending
- 2022-12-21 AU AU2022420594A patent/AU2022420594A1/en active Pending
- 2022-12-21 CA CA3240079A patent/CA3240079A1/en active Pending
- 2022-12-21 KR KR1020247024380A patent/KR20240134257A/ko active Pending
- 2022-12-21 IL IL313770A patent/IL313770A/en unknown
- 2022-12-21 US US18/069,529 patent/US20240059798A1/en active Pending
- 2022-12-21 WO PCT/US2022/082131 patent/WO2023122659A2/en not_active Ceased
- 2022-12-21 EP EP22912696.6A patent/EP4452317A4/en active Pending
-
2024
- 2024-06-19 CL CL2024001850A patent/CL2024001850A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strohl | Current progress in innovative engineered antibodies | |
| US10882922B2 (en) | Trispecific and/or trivalent binding proteins | |
| JP6622396B2 (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| US11421028B2 (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| JP2019522459A5 (cg-RX-API-DMAC7.html) | ||
| JP2021531785A5 (cg-RX-API-DMAC7.html) | ||
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| US20220396635A1 (en) | Trivalent binding molecules | |
| US20240059798A1 (en) | Conditionally activated antigen binding polypeptide complexes and methods of use thereof | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| WO2020102422A1 (en) | THERAPEUTIC SIRPα ANTIBODIES | |
| JP2023159379A (ja) | Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途 | |
| WO2020135804A1 (zh) | 异源二聚体融合蛋白 | |
| JP2023550419A5 (cg-RX-API-DMAC7.html) | ||
| JP2022545368A5 (cg-RX-API-DMAC7.html) | ||
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| RU2020115450A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и cd28 | |
| JP2024531913A5 (cg-RX-API-DMAC7.html) | ||
| RU2024102366A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и сd28 | |
| RU2023128356A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и сd28 | |
| TH1801006399A (th) | โปรตีนการจับชนิดไตรสเปซิฟิกและ/หรือไตรวาเลนต์ |